ArticleHaematologica2020

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Davine Hofste op Bruinink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.